Blood Coagulation Factor Inhibitors
"Blood Coagulation Factor Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
| Descriptor ID |
D019774
|
| MeSH Number(s) |
D23.113
|
| Concept/Terms |
Blood Coagulation Factor Inhibitors- Blood Coagulation Factor Inhibitors
- Inhibitor, Coagulation Factor, Blood
- Inhibitors, Coagulation Factor, Blood
- Inhibitor, Blood Coagulation Factor
- Inhibitors, Blood Coagulation Factor
|
Below are MeSH descriptors whose meaning is more general than "Blood Coagulation Factor Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Blood Coagulation Factor Inhibitors".
This graph shows the total number of publications written about "Blood Coagulation Factor Inhibitors" by people in this website by year, and whether "Blood Coagulation Factor Inhibitors" was a major or minor topic of these publications.
Below are the most recent publications written about "Blood Coagulation Factor Inhibitors" by people in Profiles.
-
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020 04; 13(4):313-321.
-
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 11 28; 134(22):1973-1982.
-
Hemophilia - Impact of Recent Advances on Management. Indian J Pediatr. 2020 02; 87(2):134-140.
-
Inhibitors: A Need for Eradication? Acta Haematol. 2019; 141(3):151-155.
-
Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 11; 11(11):835-846.
-
The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Rev Hematol. 2018 11; 11(11):857-862.
-
A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Rev Hematol. 2018 02; 11(2):87-97.
-
Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. Am J Hematol. 2017 Sep; 92(9):940-945.
-
Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. Haemophilia. 2017 Sep; 23(5):e394-e402.
-
Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia. 2013 May; 19(3):e151-66.